OPKO Health expects Q3 total revenue between $131 mln and $142 mln
Company sees full-year 2026 total revenue between $560 mln and $585 mln
OPKO Health projects full-year 2026 costs and expenses of $710 mln to $740 mln
Overview
US biopharma and diagnostics firm's Q2 revenue rose yr/yr, driven by higher IP and partnership revenue
Q2 net loss narrowed to $8.4 mln from $148.4 mln a year earlier
Company repurchased $13.2 mln of stock in Q2; $94.7 mln remains authorized
Result Drivers
IP and partnership revenue - Higher Q2 revenue was mainly driven by increased revenue from transfer of intellectual property and partnerships, including shares received from amended Nicoya agreement and higher revenue from NGENLA, Eli Lilly, and Regeneron
International product sales - Product revenue increased due to higher sales volumes in Spanish and Mexican operations and positive foreign exchange impact, partially offset by declines in other international markets
Service revenue decline - Revenue from services fell due to the prior-year contribution from oncology assets sold to Labcorp in September 2025
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for OPKO Health Inc is $3.00, about 145.9% above its July 24 closing price of $1.22
OPK•
